The high level of the inflammatory factor IL-1β in serum from ACLF patients can promote the expression of IL-8 in hUC-MSCs through the NF-κB signaling pathway, thereby reducing the effect of hUC-MSCs in the treatment of liver failure (Fig. 6). The gene discussed is CXCL8; the disease is Hepatic failure.